PMC2018 Mobile Header 300x76

Choosing the Best Option for Patients: Integrating GLP-1 RAs into Type 2 Diabetes Management

Type: Pre-Conference
Wednesday May 9
12:10pm to 1:10pm

  • Description

    Diabetes Canada recommends that Canadian healthcare providers select a pharmacologic treatment for type 2 diabetes mellitus (T2DM) based on specific patient and agent characteristics, emphasizing individualization. With new and emerging therapies within the GLP-1 receptor agonist (GLP-1RA) class, and updates to the guidelines, participants will review the most recently available information and how it can be applied to clinical practice. Designed by a multidisciplinary committee comprised of family physicians, pharmacists and an endocrinologist, this program highlights common scenarios in which GLP-1RAs may be considered, and provides participants with an opportunity to “build” and discuss a patient case.

    Learning Objectives
    • Assess the role of GLP-1 receptor agonist (GLP-1RA) therapy in T2DM, focusing on recommendations from Diabetes Canada.
    • Compare and contrast the efficacy, safety and dosing of current and upcoming GLP-1RAs.
    • Discuss how to integrate the GLP-1RA class into practice, reflecting on specific patient and agent characteristics to optimize T2DM management.

    Accreditation Statement:
    This Group Learning program has been reviewed by the College of Family Physicians of Canada and is awaiting final certification by the College’s Ontario Chapter.

    Industry Support
    This program was supported in part by an educational grant from Novo Nordisk.
  • Speakers